Release Date: January 17, 2019
Expiration Date: January 17, 2021
Estimated Time of Completion: 30 minutes
Description
Pirating on Rough Waters: CAR Therapy for Myeloid Neoplasms webcast, part of the Riding the Wave: Clinical Management of Myeloid Malignancies in an Era of Novel Therapies online series, will review CAR design and CD19 CAR experience, as well as AML CAR target identification challenges.
Learning Objectives
- Review basic CAR design and CD19 CAR experience
- Describe AML CAR target identification challenges
- Identify BiTE and DART therapeutic approaches in AML
- Highlight AML CAR clinical experience to date and future AML CAR (ASH 2018 and beyond)
- Critically appraise results of research on the evolving role of chimeric antigen receptor-T cell (CAR-T) therapy in myeloid malignancies
Target Audience
This educational activity is designed for an international audience including medical oncologists/hematologists, clinical and translational researchers, and other physicians and allied health care professionals treating patients with MDS and other bone marrow failure diseases. In addition, members of patient advocacy groups will benefit from this program.
Accreditation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The Cleveland Clinic Foundation Center for Continuing Education and Aplastic Anemia & MDS International Foundation. The Cleveland Clinic Foundation Center for Continuing Education is accredited by the ACCME to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit.
Activity Director and Faculty
Activity Director
Matt Kalaycio, MD
Chair, Department of Hematology and Medical Oncology
Taussig Cancer Institute
Cleveland Clinic
Cleveland, OH
Faculty
Jae Park, MD
Memorial Sloan Kettering Cancer Center
New York, NY
CME Disclaimer
The information in this educational activity is provided for general medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition. The viewpoints expressed in this CME activity are those of the authors/faculty. They do not represent an endorsement by The Cleveland Clinic Foundation. In no event will The Cleveland Clinic Foundation be liable for any decision made or action taken in reliance upon the information provided through this CME activity.
Disclosures
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he has a relationship, which in the context of his presentation(s), could be perceived as a potential conflict of interest:
| Jae Park, MD |
| |
Amgen, Kite Pharma Inc.
Novartis Pharmaceuticals |
Consulting |
The following faculty has indicated he has no relationship which, in the context of his presentation(s), could be perceived as a potential conflict of interest:
Matt Kalaycio, MD |
Acknowledgment
The Cleveland Clinic Foundation Center for Continuing Education
acknowledges educational grants for partial support of the Internet Enduring activity from:
Alexion Pharmaceuticals, Inc.
Apellis Pharmaceuticals
Celgene Corporation
Geron Corporation
Millennium Pharmaceuticals, Inc.
Onconova Therapeutics, Inc.
RA Pharmaceuticals, Inc.
This CME activity was produced by the Cleveland Clinic Foundation Center for Continuing Education,
Cleveland Clinic’s Taussig Cancer Institute and Aplastic Anemia & MDS International Foundation.
